Regular Article
The use of a prognostic table to aid decision making on adjuvant therapy for women with early breast cancer

https://doi.org/10.1053/ejso.2002.1300Get rights and content

Abstract

Aim: Understanding the likely net benefit of chemotherapy for the individual patient helps physicians to give objective information. A prognostic table has been constructed detailing the percentage absolute survival advantage offered by polychemotherapy for patients with early breast cancer, according to their age and the Nottingham Prognostic Index of their tumour. This study aims to assess its first year of use in the Leicestershire Breast Unit.

Method:Demographic, pathological and treatment data were collected prospectively onto the Leicestershire breast cancer database. Patients with a potential survival advantage of 2% or greater in the year 01/05/99 to 30/04/00 (after the prognostic table was used routinely to determine oncology referrals) were identified. Chemotherapy usage was compared with the previous year's patient group.

Results: Two hundred and eighty-eight had early breast cancer, requiring surgery, eligible for consideration of adjuvant therapy. Of these, 98% of women with a potential survival advantage of 6% or more received chemotherapy. Ninety-one percent of those with a survival advantage of 4% or more was seen by an oncologist. Of those with a 2% survival advantage, 48% were referred to discuss the issues with an oncologist. Use of the table resulted in increased chemotherapy rates for women with a 4% potential survival advantage.

Conclusions: We have found the prognostic table to be a useful and workable tool and advocate its use.

References (11)

There are more references available in the full text version of this article.

Cited by (20)

  • A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation

    2016, International Journal of Cardiology
    Citation Excerpt :

    In conclusion, our findings, either showing an advantage over the actual practice of the model versions that would treat the highest proportion of patients, or showing the advantage of a decisional strategy that does not formally include the bleeding risk assessment, point out the need of educational interventions and support to counteract the concern about anticoagulation. On the other end, we want to emphasize that as with any impact study, even when randomized, this by definition evaluates the impact of a decisional model on average, i.e. at a population level [9,26,27]. At the individual level, a decisional strategy that takes into account whenever possible the specific patient's risks, needs, and preferences sounds always as the most appropriate one.

  • Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999

    2007, European Journal of Cancer
    Citation Excerpt :

    Allied to that, case survival has risen. As the NPI is widely used in clinical practice,15 in the estimation of causation in legal reports and as the best present gold standard as a basis of comparison for new prognostic methods,8 there has been a good deal of demand for figures based on modern day diagnosis and case management to be provided. Updated survival figures on the whole Nottingham-Tenovus series (1973–2000) and on cancers treated in 1990–1999 were reported in an invited paper over-viewing the NPI in 2002.16

  • Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: An increase in cell number at completion of therapy is a predictor of early relapse

    2007, Breast
    Citation Excerpt :

    This is within the same range as usually expected in comparable populations.1 According to their risk profile20 patients with good prognostic parameters (N0) were treated with EC only, whereas patients with inferior prognostic parameters (N1) received additional taxol cycles21 or CMF. Early relapses have so far occurred only in the patients with less favourable prognostic markers during the observation time of up to 4.5 years.

View all citing articles on Scopus
f1

Correspondence to: Melanie Feldman, c/o Miss A Stotter, Dept. General Surgery, Glenfield Hospital, Groby Road, Leicester LE3 9PQ, UK. E-mail: [email protected]

View full text